Exosome-based therapies represent a pioneering frontier in cancer treatment, leveraging the natural cellular communication mechanisms encapsulated in exosomes. These nano-sized vesicles serve as carriers of proteins, lipids, and nucleic acids, reflecting the physiological state of their cells of origin, which makes them ideal candidates for targeted cancer therapies and diagnostics. Despite their potential, the path to clinical application is fraught with challenges. This review explores the inherent challenges associated with exosome-based cancer vaccines, focusing on tumor heterogeneity, the technical difficulties in exosome isolation and characterization, the need for standardized protocols, and the scalability of production methods. It also explores the interaction between exosomes and the immune system, a crucial factor in developing effective cancer vaccines. The review explores strategies to improve diagnostic tools, targeted delivery systems, and therapy based on individual tumor profiles, highlighting the need for innovative approaches and collaborative efforts to maximize exosome-based cancer vaccines' therapeutic potential.
Mukerjee et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: